Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

HIV Care in the COVID-19 Era: Differentiated Delivery Models Beyond Telemedicine
  • CME
  • CE

Credits Available
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
Registered Nurses: 0.5 Nursing contact hours
Pharmacists: 0.5 contact hours (0.05 CEUs)
Released: July 30, 2021 Expiration: July 29, 2022
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This program is supported by an educational grant from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
Monica Gandhi, MD, MPH
Jürgen K. Rockstroh, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe evidence supporting the feasibility and efficacy of differentiated models of HIV service delivery utilized during the COVID-19 pandemic

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Jürgen K. Rockstroh, MD

Professor of Medicine
University Hospital Bonn
Department of Medicine I
Bonn, Germany

Jürgen K. Rockstroh, MD, has disclosed that he has received consulting fees from Abivax, Galapagos, Gilead Sciences, Merck, and ViiV and fees for non-CME/CE services from Gilead Sciences, Janssen, Merck, and ViiV.
Monica Gandhi, MD, MPH

Professor of Medicine
Division of HIV, Infectious Diseases, and Global Medicine
University of California, San Francisco
Medical Director
Ward 86 HIV Clinic
San Francisco General Hospital
San Francisco, California

Monica Gandhi, MD, MPH, has no relevant conflicts of interest to report.

Staff

Margaret McLaughlin, PhD
Margaret McLaughlin, PhD, has no relevant conflicts of interest to report.
Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer M. Blanchette, PhD, has no relevant conflicts of interest to report.
Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Jennifer Swanson, PharmD

Editorial Contributor

Jennifer Swanson, PharmD, has no relevant conflicts of interest to report.
Julie Skowronski, FNP-BC
Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.
Edward King, MA

Executive Vice President

Edward King, MA, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, registered nurses, pharmacists, and other healthcare providers who care for persons living with HIV in the time of COVID-19.

Goal

The goal of this activity is to improve clinicians’ competence in providing optimal HIV care despite the changing impact of COVID-19 on patient management.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-137-H02-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 100% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 30, 2021, through July 29, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

HIV Care in the COVID-19 Era: Differentiated Delivery Models Beyond Telemedicine
  • CME
  • CE

Loading...
In this call between colleagues, expert faculty discuss what they learned during the COVID-19 pandemic about how healthcare professionals and healthcare systems need to be creative when it comes to HIV care and service delivery to find solutions that go beyond telemedicine and further expand the reach of care, including for the most vulnerable populations.
Monica Gandhi, MD, MPH
Jürgen K. Rockstroh, MD
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
Registered Nurses: 0.5 Nursing contact hours
Pharmacists: 0.5 contact hours (0.05 CEUs)
Released: July 30, 2021 Expiration: July 29, 2022

Related Content

Dr Milena Murray and Clinical Care Options (CCO): ART-associated gestational weight gain, pregnancy effects, and the impact of baseline maternal weight

person default Milena Murray, PharmD, MSc, BCIDP, AAHIVP Released: September 21, 2021

Concise Clinical Care Options (CCO) presentation by Colleen Kelley, MD, MPH, on investigational long-acting HIV PrEP regimens in late stages of clinical development

Colleen Kelley, MD, MPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: September 20, 2021 Expired: September 19, 2022

CCO slides from Dr. Colleen Kelley, on investigational long-acting HIV PrEP regimens in late stages of clinical development

Colleen Kelley, MD, MPH Released: September 20, 2021

Dr Milena Murray and Clinical Care Options (CCO): Current pharmacokinetic and safety data support the use of tenofovir alafenamide during pregnancy

person default Milena Murray, PharmD, MSc, BCIDP, AAHIVP Released: September 15, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This program is supported by an educational grant from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue